139 related articles for article (PubMed ID: 36314449)
21. Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors.
McCluggage WG; Young RH
Semin Diagn Pathol; 2005 Feb; 22(1):3-32. PubMed ID: 16512597
[TBL] [Abstract][Full Text] [Related]
22. Ovarian Endometrioid Carcinoma Misdiagnosed as Mucinous Carcinoma: An Underrecognized Problem.
Woodbeck R; Kelemen LE; Köbel M
Int J Gynecol Pathol; 2019 Nov; 38(6):568-575. PubMed ID: 30480647
[TBL] [Abstract][Full Text] [Related]
23. Cases of Yolk sac tumor associated with gynecological malignant tumor.
Wang S; Chen K; Chen Q; Huang S; Lu W
BMC Womens Health; 2023 Jun; 23(1):348. PubMed ID: 37391759
[TBL] [Abstract][Full Text] [Related]
24. Role of HNF1β in the differential diagnosis of yolk sac tumor from other germ cell tumors.
Rougemont AL; Tille JC
Hum Pathol; 2018 Nov; 81():26-36. PubMed ID: 29753846
[TBL] [Abstract][Full Text] [Related]
25. Ovarian yolk sac tumor in postmenopausal females: a report of five cases and a literature review.
Wang X; He J; Li Y
Eur J Gynaecol Oncol; 2016; 37(3):374-9. PubMed ID: 27352567
[TBL] [Abstract][Full Text] [Related]
26. Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Jin JS; Hsieh DS; Loh SH; Chen A; Yao CW; Yen CY
Mod Pathol; 2006 Mar; 19(3):447-52. PubMed ID: 16439987
[TBL] [Abstract][Full Text] [Related]
27. Gonadoblastoma and hepatoid and endometrioid-like yolk sac tumor: an update.
Ulbright TM
Int J Gynecol Pathol; 2014 Jul; 33(4):365-73. PubMed ID: 24901396
[TBL] [Abstract][Full Text] [Related]
28. Yolk Sac Tumor in Extragonadal Pelvic Sites: Still a Diagnostic Challenge.
Ravishankar S; Malpica A; Ramalingam P; Euscher ED
Am J Surg Pathol; 2017 Jan; 41(1):1-11. PubMed ID: 27631522
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of lymphadenectomy and prevalence of lymph node metastasis in clinically-apparent stage I endometrioid and mucinous ovarian carcinoma.
Nasioudis D; Chapman-Davis E; Witkin SS; Holcomb K
Gynecol Oncol; 2017 Feb; 144(2):414-419. PubMed ID: 27908528
[TBL] [Abstract][Full Text] [Related]
30. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'.
Lee KR; Scully RE
Am J Surg Pathol; 2000 Nov; 24(11):1447-64. PubMed ID: 11075847
[TBL] [Abstract][Full Text] [Related]
31. Primary germ cell tumors of the mediastinum: III. Yolk sac tumor, embryonal carcinoma, choriocarcinoma, and combined nonteratomatous germ cell tumors of the mediastinum--a clinicopathologic and immunohistochemical study of 64 cases.
Moran CA; Suster S; Koss MN
Cancer; 1997 Aug; 80(4):699-707. PubMed ID: 9264353
[TBL] [Abstract][Full Text] [Related]
32. Endometriosis-associated epithelial ovarian cancer is a more complicated disease than we suspected before.
Yang ST; Chang WH; Lee NR; Lai WA; Shen SH; Lee WL; Wang PH
Taiwan J Obstet Gynecol; 2021 Nov; 60(6):1112-1115. PubMed ID: 34794748
[TBL] [Abstract][Full Text] [Related]
33. Malignant ovarian tumor composed of endometrioid adenocarcinoma, clear cell adenocarcinoma, squamous cell carcinoma, yolk sac tumor and immature teratoma with prominent neuroectodermal and rhabdomyosarcomatous differentiation: a case study.
Ohishi Y; Kaku T; Kaneki E; Wake N; Tsuneyoshi M
Gynecol Oncol; 2007 May; 105(2):548-52. PubMed ID: 17341430
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
Skírnisdóttir I; Seidal T
Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
[TBL] [Abstract][Full Text] [Related]
35. Bilateral ovarian mixed epithelial adenocarcinoma in a postmenopausal woman with unilateral ovarian yolk sac tumor component.
Chen Q; Chen X
Int J Clin Exp Pathol; 2014; 7(11):8259-65. PubMed ID: 25550883
[TBL] [Abstract][Full Text] [Related]
36. Usefulness of endometrial aspiration cytology for the preoperative diagnosis of ovarian carcinoma.
Jobo T; Arai M; Iwaya H; Kato Y; Ohno E; Kuramoto H
Acta Cytol; 1999; 43(2):104-9. PubMed ID: 10097693
[TBL] [Abstract][Full Text] [Related]
37. Cancer stem cell and embryonic development-associated molecules contribute to prognostic significance in ovarian cancer.
Oktem G; Sanci M; Bilir A; Yildirim Y; Kececi SD; Ayla S; Inan S
Int J Gynecol Cancer; 2012 Jan; 22(1):23-9. PubMed ID: 22080880
[TBL] [Abstract][Full Text] [Related]
38. AGR2 expression in ovarian tumours: a potential biomarker for endometrioid and mucinous differentiation.
Armes JE; Davies CM; Wallace S; Taheri T; Perrin LC; Autelitano DJ
Pathology; 2013 Jan; 45(1):49-54. PubMed ID: 23222243
[TBL] [Abstract][Full Text] [Related]
39. Primary Endometrial Yolk Sac Tumor With Endodermal-Intestinal Differentiation Masquerading as Metastatic Colorectal Adenocarcinoma.
Damato S; Haldar K; McCluggage WG
Int J Gynecol Pathol; 2016 Jul; 35(4):316-20. PubMed ID: 26598980
[TBL] [Abstract][Full Text] [Related]
40. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
